OC
NGNE icon

Oppenheimer & Co’s Neurogene NGNE Stock Holding History

Oppenheimer & Co’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-760
Closed -$110K – 1537
2021
Q3 		$110K Buy
760
+51
+7% +$7.81K ﹤0.01% 1445
2021
Q2 		$131K Sell
709
-16
-2% -$3.54K ﹤0.01% 1456
2021
Q1 		$178K Buy
725
+4
+0.6% +$1.02K ﹤0.01% 1362
2020
Q4 		$203K Buy
721
+33
+5% +$8.06K ﹤0.01% 1245
2020
Q3 		$165K Buy
+688
New +$167K ﹤0.01% 1184

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Oppenheimer & Co's NGNE Position: Q4 2021 in Review

Oppenheimer & Co sold out of Neurogene (NGNE) in Q4 2021, closing a stake of 760 shares — an estimated $110K sold.

Oppenheimer & Co first reported a position in NGNE in Q3 2020 and held it in 5 quarters. The position peaked at $203K in Q4 2020. 80 funds tracked by Wall St. Rank hold NGNE as of Q4 2021.

  • Oppenheimer & Co reported no remaining Neurogene position as of Q4 2021 after selling out during the quarter.
  • Oppenheimer & Co sold 760 Neurogene shares in Q4 2021, an estimated $110K.
  • Oppenheimer & Co first reported a position in Neurogene in Q3 2020 and held it in 5 quarters.
  • Oppenheimer & Co's Neurogene position peaked at $203K in Q4 2020.
  • 80 funds tracked by Wall St. Rank held Neurogene as of Q4 2021.

Based on Oppenheimer & Co's 13F filing for Q4 2021, filed 2 Feb 2022.